Evidence of bendamustine plus rituximab for old and frail patients with aggressive B-cell lymphoma.
作者信息
Schalk Enrico, Jentsch-Ullrich Kathleen
机构信息
Department of Hematology and Oncology, Medical Center, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120, Magdeburg, Germany.
Practice for Hematology and Oncology, Magdeburg, Germany.
出版信息
Ann Hematol. 2023 Jun;102(6):1617-1620. doi: 10.1007/s00277-023-05166-w. Epub 2023 Mar 16.
Abstract
摘要
相似文献
1
Evidence of bendamustine plus rituximab for old and frail patients with aggressive B-cell lymphoma.苯达莫司汀联合利妥昔单抗用于老年体弱侵袭性B细胞淋巴瘤患者的证据。
Ann Hematol. 2023 Jun;102(6):1617-1620. doi: 10.1007/s00277-023-05166-w. Epub 2023 Mar 16.
2
[Bendamustine plus rituximab as first-line treatment in patients with indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma : a real-world study in China].苯达莫司汀联合利妥昔单抗作为惰性B细胞非霍奇金淋巴瘤和套细胞淋巴瘤患者的一线治疗：中国的一项真实世界研究
Zhonghua Xue Ye Xue Za Zhi. 2023 Apr 14;44(4):333-336. doi: 10.3760/cma.j.issn.0253-2727.2023.04.012.
3
A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.苯达莫司汀联合利妥昔单抗治疗既往接受过利妥昔单抗治疗的复发或难治性惰性B细胞非霍奇金淋巴瘤和套细胞淋巴瘤日本患者的II期研究：BRB研究
Int J Hematol. 2015 Jun;101(6):554-62. doi: 10.1007/s12185-015-1767-3. Epub 2015 Mar 19.
4
Bendamustine-rituximab in mantle cell lymphoma.苯达莫司汀-利妥昔单抗治疗套细胞淋巴瘤
Lancet Haematol. 2017 Jan;4(1):e2-e3. doi: 10.1016/S2352-3026(16)30187-9. Epub 2016 Dec 5.
5
Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.苯达莫司汀联合利妥昔单抗用于既往未治疗的惰性B细胞非霍奇金淋巴瘤或套细胞淋巴瘤患者：日本一项多中心II期临床试验
Int J Hematol. 2017 Apr;105(4):470-477. doi: 10.1007/s12185-016-2146-4. Epub 2016 Nov 29.
6
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.一项在不适合移植、未经治疗的套细胞淋巴瘤患者中比较泽布替尼联合利妥昔单抗与苯达莫司汀联合利妥昔单抗的 III 期研究。
Future Oncol. 2021 Jan;17(3):255-262. doi: 10.2217/fon-2020-0794. Epub 2020 Sep 28.
7
The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.苯达莫司汀的发现和发展用于治疗非霍奇金淋巴瘤。
Expert Opin Drug Discov. 2016 Nov;11(11):1123-1130. doi: 10.1080/17460441.2016.1233174. Epub 2016 Sep 16.
8
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.利妥昔单抗、苯达莫司汀和小剂量阿糖胞苷作为老年套细胞淋巴瘤患者的诱导治疗：来自意大利淋巴瘤基金会的一项多中心2期试验
Lancet Haematol. 2017 Jan;4(1):e15-e23. doi: 10.1016/S2352-3026(16)30185-5. Epub 2016 Dec 5.
9
Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study.苯达莫司汀联合利妥昔单抗作为复发或难治性低度B细胞淋巴瘤和套细胞淋巴瘤患者的挽救治疗：一项单中心回顾性研究。
Acta Med Okayama. 2021 Aug;75(4):461-469. doi: 10.18926/AMO/62398.
10
Rituximab, bendamustine and cytarabine (R-BAC) in patients with relapsed-refractory aggressive B-cell lymphoma.利妥昔单抗、苯达莫司汀和阿糖胞苷（R-BAC）用于复发难治性侵袭性B细胞淋巴瘤患者。
Am J Hematol. 2018 Dec;93(12):E386-E389. doi: 10.1002/ajh.25278. Epub 2018 Oct 9.
本文引用的文献
1
First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial.苯达莫司汀联合利妥昔单抗一线治疗老年体弱侵袭性淋巴瘤患者：B-R-ENDA试验结果
Hemasphere. 2022 Dec 1;6(12):e808. doi: 10.1097/HS9.0000000000000808. eCollection 2022 Dec.
2
Retrospective studies - utility and caveats.回顾性研究——实用性及注意事项。
J R Coll Physicians Edinb. 2020 Dec;50(4):398-402. doi: 10.4997/JRCPE.2020.409.
3
Is bendamustine-rituximab a reasonable treatment in selected older patients with diffuse large B cell lymphoma? Results from a multicentre, retrospective study.苯达莫司汀-利妥昔单抗治疗选择的老年弥漫性大 B 细胞淋巴瘤患者是否合理？来自多中心回顾性研究的结果。
Ann Hematol. 2019 Dec;98(12):2729-2737. doi: 10.1007/s00277-019-03819-3. Epub 2019 Nov 8.
4
Comparison of Comorbidity and Frailty Indices in Patients With Head and Neck Cancer Using an Online Tool.使用在线工具对头颈部癌患者的合并症和衰弱指数进行比较。
JCO Clin Cancer Inform. 2018 Dec;2:1-9. doi: 10.1200/CCI.18.00082.
5
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting.真实世界中弥漫性大B细胞淋巴瘤（DLBCL）患者的24个月无进展生存期（PFS24）及后续转归。
Ann Oncol. 2019 Jan 1;30(1):151-152. doi: 10.1093/annonc/mdy482.
6
Rituximab plus bendamustine as front-line treatment in frail elderly (>70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the .利妥昔单抗联合苯达莫司汀作为一线治疗在体弱老年（>70 岁）弥漫性大 B 细胞非霍奇金淋巴瘤患者中的应用：一项. 的多中心 II 期研究
Haematologica. 2018 Aug;103(8):1345-1350. doi: 10.3324/haematol.2017.186569. Epub 2018 May 10.
7
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study.含利妥昔单抗方案治疗弥漫性大 B 细胞淋巴瘤中性别与预后的关系：一项意大利淋巴瘤基金会/恶性血液病研究协作组的回顾性研究。
Leuk Lymphoma. 2013 Jan;54(1):53-7. doi: 10.3109/10428194.2012.691482. Epub 2012 Sep 28.
8
Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.标准国际预后指数仍然是利妥昔单抗时代侵袭性 CD20+ B 细胞淋巴瘤患者预后的有效预测指标。
J Clin Oncol. 2010 May 10;28(14):2373-80. doi: 10.1200/JCO.2009.26.2493. Epub 2010 Apr 12.
9
Comorbidity and functional status are independent in older cancer patients.合并症与功能状态在老年癌症患者中相互独立。
J Clin Oncol. 1998 Apr;16(4):1582-7. doi: 10.1200/JCO.1998.16.4.1582.
Zotero 插件